Article Text

Download PDFPDF
DNA hypermethylation analysis in sputum of asymptomatic subjects at risk for lung cancer participating in the NELSON trial: argument for maximum screening interval of 2 years
  1. A Jasmijn Hubers1,
  2. Daniëlle A M Heideman1,
  3. Sylvia Duin1,
  4. Birgit I Witte2,
  5. Harry J de Koning3,
  6. Harry J M Groen4,
  7. Clemens F M Prinsen5,
  8. Anne S Bolijn1,5,
  9. Mandy Wouters5,
  10. Susanne E van der Meer5,
  11. Renske D M Steenbergen1,
  12. Peter J F Snijders1,
  13. Anne Uyterlinde1,
  14. Hans Berkhof2,
  15. Egbert F Smit6,
  16. Erik Thunnissen1
  1. 1Department of Pathology, VU University Medical Center, Amsterdam, The Netherlands
  2. 2Department of Epidemiology and Biostatistics, VU University Medical Center, Amsterdam, The Netherlands
  3. 3Department of Public Health, Erasmus Medical Center, Rotterdam, The Netherlands
  4. 4Department of Pulmonary Diseases, University Medical Center Groningen, Groningen, The Netherlands
  5. 5Department of Pathology, Canisius-Wilhelmina Hospital, Nijmegen, The Netherlands
  6. 6Department of Pulmonary Diseases, VU University Medical Center, Amsterdam, The Netherlands
  1. Correspondence to Dr Erik Thunnissen, Department of Pathology, VU University Medical Center, De Boelelaan 1117, Amsterdam 1081 HV, The Netherlands; e.thunnissen{at}vumc.nl

Footnotes

  • Handling editor Runjan Chetty

  • Funding This study was funded by Dutch Cancer Society (grant VU2008-4220) and Perceptronix Medical (Vancouver, Canada).

  • Competing interests HJdK reports grants from ZonMw, Dutch Cancer Society, RVVZ, Roche Diagnostics, other from Siemens Germany and LungCARE, during the conduct of the study. ET reports grants for sputum examination from Dutch Cancer Society, MdxHealth.

  • Ethics approval Dutch Ministry of Health (NL 22206.029.08) and the Institutional Review Boards.

  • Provenance and peer review Not commissioned; externally peer reviewed.

View Full Text

Statistics from Altmetric.com

Footnotes

  • Handling editor Runjan Chetty

  • Funding This study was funded by Dutch Cancer Society (grant VU2008-4220) and Perceptronix Medical (Vancouver, Canada).

  • Competing interests HJdK reports grants from ZonMw, Dutch Cancer Society, RVVZ, Roche Diagnostics, other from Siemens Germany and LungCARE, during the conduct of the study. ET reports grants for sputum examination from Dutch Cancer Society, MdxHealth.

  • Ethics approval Dutch Ministry of Health (NL 22206.029.08) and the Institutional Review Boards.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.